Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs AXT Inc (AXTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs AXT Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while AXT Inc trades at $55.31 (market cap $3.74B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.7× AXT Inc's market cap, and AXT Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AXTI | |
|---|---|---|
Market Cap | $39.89B | $3.74B |
Sector | Health | Technology |
52-Week High | $491.22 | $140.83 |
52-Week Low | $278.09 | $1.92 |
Enterprise Value | $38.15B | $3.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
AXTI trades at $57.21, down 8.54% today amid bearish technical signals. The company shows negative profitability with a -14.68% net margin but has beaten EPS estimates in two of the last three quarters. Analyst consensus is bullish with 64% buy ratings, supported by a $100M backlog and AI-driven indium phosphide demand growth. Cash flow remains positive primarily from financing activities.
Near-term outlook hinges on Q2 2026 earnings due July 30, where analysts expect EPS of $0.07. Key opportunities include AI infrastructure expansion and capacity growth, while risks involve geopolitical tensions affecting Chinese exports and ongoing negative cash flow from operations. The stock faces resistance near $66 with support at $55.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →
